stockportfolio.pro
Cytokinetics, Incorporated Net Income 1999–2025
Cytokinetics, Incorporated (CYTK) annual net income by fiscal year, computed from SEC filings.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $-784.96M | -891.6% | -33.2% |
| FY 2024 | $-589.53M | -3191.1% | -12.0% |
| FY 2023 | $-526.24M | -6988.6% | -35.3% |
| FY 2022 | $-388.95M | -411.2% | -80.6% |
| FY 2021 | $-215.31M | -305.7% | -69.2% |
| FY 2020 | $-127.29M | -228.0% | -4.6% |
| FY 2019 | $-121.69M | -452.9% | -14.5% |
| FY 2018 | $-106.29M | -337.4% | +16.8% |
| FY 2017 | $-127.79M | -955.9% | -876.7% |
| FY 2016 | $16.45M | 15.5% | +143.9% |
| FY 2015 | $-37.50M | -130.9% | -156.0% |
| FY 2014 | $-14.65M | -31.2% | +56.6% |
| FY 2013 | $-33.72M | -110.0% | +16.5% |
| FY 2012 | $-40.37M | -534.1% | +15.6% |
| FY 2011 | $-47.86M | -1196.5% | +2.9% |
| FY 2010 | $-49.29M | -1912.6% | -300.8% |
| FY 2009 | $24.54M | 30.1% | +143.5% |
| FY 2008 | $-56.37M | — | -15.3% |
| FY 2007 | $-48.89M | — | +14.4% |
| FY 2006 | $-57.12M | — | -35.2% |
| FY 2005 | $-42.25M | — | -13.6% |
| FY 2004 | $-37.20M | — | -13.8% |
| FY 2003 | $-32.69M | — | -41.6% |
| FY 2002 | $-23.08M | — | -45.4% |
| FY 2001 | $-15.87M | — | -21.4% |
| FY 2000 | $-13.08M | — | -78.2% |
| FY 1999 | $-7.34M | — | — |
Source: Cytokinetics, Incorporated SEC filings — income statement (10-K). Refreshed nightly.
See the full picture for Cytokinetics, Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytokinetics, Incorporated — frequently asked questions
What is Cytokinetics, Incorporated's net income?
Cytokinetics, Incorporated (CYTK) reported net income of $-784.96M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Cytokinetics, Incorporated's official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.